Dr. Inzucchi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
789 Howard Avenue 2nd Floor
Dana Building
New Haven, CT 06510
Education & Training
- Yale-New Haven Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1992 - 1994
- Yale-New Haven Medical CenterResidency, Internal Medicine, 1985 - 1987
- Harvard Medical SchoolClass of 1985
Certifications & Licensure
- CT State Medical License 1987 - 2025
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2008-2014
- New York Magazine: Top Doctors Castle Connolly, 2007-2014
- Top Doctors: New York Metro Area Castle Connolly, 2006-2014
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsEffect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial.Rahul Aggarwal, Deepak L Bhatt, Michael Szarek, Christopher P Cannon, Lawrence A Leiter
The Lancet. Diabetes & Endocrinology. 2025-04-01 - Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.Darren K McGuire, Nikolaus Marx, Sharon L Mulvagh, John E Deanfield, Silvio E Inzucchi
The New England Journal of Medicine. 2025-03-29 - Oral Semaglutide and Cardiovascular Outcomes in Persons With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial.Nikolaus Marx, John E Deanfield, Johannes F E Mann, Rosario Arechavaleta, Stephen C Bain
Circulation. 2025-03-29
Journal Articles
- Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME TrialSilvio Inzucchi, MD, Journal of the American Society of Nephrology
- Cardiovascular Safety of Lorcaserin in Overweight or Obese PatientsErin A Bohula, Stephen D Wiviott, Benjamin M Scirica, Darren K McGuire, Marc S Sabatine, Marc P Bonaca, Christian T Ruff, Silvio E Inzucchi, The New England Journal of Medicine
- Cardiovascular Safety of Lorcaserin in Overweight or Obese PatientsChristina L. Fanola, Darren K. McGuire, Silvio E. Inzucchi, Erin A. Bohula, The New England Journal of Medicine
Lectures
- Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk MarkersAmerican Heart Association, Scientific Sessions 2010, Chicago, Illinois, USA
- Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk MarkersScientific Sessions 2008, New Orleans, Louisiana, USA
- Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk MarkersScientific Sessions 2010, Chicago, Illinois, USA
- Join now to see all
Other
- Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk MarkersSilvio Inzucchi, MD, Diabetes, Obesity and Metabolism
https://www.doximity.com/articles/b552b1a0-ea89-475a-8388-913374468095
UpToDate, Wolters Kluwer Health - 2012-07-30 - Oral Pharmacologic Treatment of Type 2 Diabetes MellitusSilvio Inzucchi, MD, Annals of Internal Medicine
https://www.doximity.com/articles/dea6d159-a396-4c8a-8d46-4b009fecfb26
UpToDate, Wolters Kluwer Health - 2012-05-24
Press Mentions
- SGLT2 Inhibitors Cut AFib Risk in Real-Word AnalysisJune 13th, 2022
- SGLT2 Inhibitors Cut AFib Risk in Real-Word AnalysisJune 13th, 2022
- Explaining Insulin Resistance, and How to Reverse ItOctober 25th, 2021
- Join now to see all
Grant Support
- GRADE TrialNIDDK2013–2020
- IRIS TrialNINDS2004–2016
- Dosage According To IGF1 Response In Growth Hormone DefiNational Center For Research Resources2000–2001
- Effects Of Troglitazone And Metformin On Glucose MetabolismNational Center For Research Resources1996–1999
- Ovine CRH In Evaluation Of Cushing SyndromeNational Center For Research Resources1997
- Endocrine Evaluation Of Patients With Diseases Of The PituitaryNational Center For Research Resources1996–1997
- Effects Of Growth Hormone Replacement In GH Deficient AdultsNational Center For Research Resources1996
Professional Memberships
- Member
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: